Dr. Davila’s bibliography includes high-impact articles in Science Advances, Nature, International Journal of Hematology, The Lancet, and New England Journal of Medicine.
Recent publications
- Beatty NJ, et al. CD28 co-stimulatory domain enhances efficacy of CER T cell therapy compared to 4-1BB in an ovarian cancer mouse model. Sci Rep. 2026 Mar 11;16(1):13068. doi: 10.1038/s41598-026-43225-0. PMID: 41813798; PMCID: PMC13099968.
- Goala P, et al. IFN-γ-driven skewing towards Th1 over Th17 differentiation underlies CRS and neutropenia in CAR-T therapy. J Clin Invest. 2025 Oct 30;136(1):e194631. doi: 10.1172/JCI194631. PMID: 41165751; PMCID: PMC12721892.
- Sailer CJ, et al. Calibrating Chimeric Antigen Receptor (CAR) Signaling to Improve CAR T-Cell Therapies. J Clin Oncol. 2025 Jul 20;43(21):2429-2432. doi: 10.1200/JCO-24-02792. Epub 2025 Jun 18. PMID: 40532128.
- Faramand RG, et al. Baseline serum inflammatory proteins predict poor CAR T outcomes in diffuse large B-cell lymphoma. Blood Cancer Discov. 2024 Mar 1;5(2):106-113.
- Boucher JC, S et al. Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia. Mol Ther Oncolytics. 2023 Dec 19;31:100751.
- Rejeski K, et al. Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion. Sci Adv. 2023 Sep 22;9(38):eadg3919.
- Dong N, et al. Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma. Transplant Cell Ther. 2023 Jun;29(6):349.e1-349.e8.
- Lee DH, et al. Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory study. Cardiooncology. 2023 Apr 1;9(1):18.
- Stein-Thoeringer CK, et al. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nat Med. 2023 Apr;29(4):906-916.
- Holtan SG, et al. Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality. Clin Cancer Res. 2023 Mar 14;29(6):1114-1124.
- Sallman DA, et al. CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial. Lancet Haematol. 2023 Mar;10(3):e191-e202.
- Boucher JC, et al. Large Scale Ex Vivo Expansion of γδ T cells Using Artificial Antigen-presenting Cells. J Immunother. 2023 Jan 1;46(1):5-13.
Connect with the Davila Lab
Email Dr. DavilaConnect on LinkedIn
Department of Immunology
Roswell Park Comprehensive Cancer Center
Elm and Carlton Streets
Buffalo, NY 14263